10 terminated. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Terminated 10 |
| Phase 2 | 1 | Terminated 1 |
Follow Urinary Bladder, Overactive: new trials by email Literature Review of Urinary Bladder, Overactive trials Research Report on Urinary Bladder, Overactive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) Mirabegron, Placebo - Overactive Bladder (OAB), Pharmacokinetics of Mirabegron | Phase 3 | Terminated | Astellas Pharma Global Development, Inc. | 26 | 2021-03-15 | 2024-11-14 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 Botulinum toxin type A, Placebo - Urinary Incontinence, Overactive Bladder | Phase 3 | Terminated | Ipsen | 258 | 2016-07-08 | 2022-09-28 |
| Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer Succinate of Solifenacin, Placebo of Succinate of Solifenacin - Overactive Bladder | Phase 3 | Terminated | Center Eugene Marquis | 4 | 2016-07-01 | 2018-01-19 |
| Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1 Botulinum toxin type A, Placebo - Urinary Incontinence, Overactive Bladder | Phase 3 | Terminated | Ipsen | 227 | 2016-03-01 | 2022-09-28 |
| Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder Bryophyllum - Overactive Bladder, Urge Urinary Incontinence | Phase 2 / Phase 3 | Terminated | University of Zurich | 9 | 2014-05-01 | 2017-10-26 |
| Over Active Bladder Instillation Study - Botox Botox Instillation, DMSO Instillation - Overactive Bladder, Urinary Urge Incontinence | Phase 3 | Terminated | Mayo Clinic | 25 | 2008-04-01 | 2014-07-11 |
| Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder botulinum toxin Type A, Normal Saline (Placebo) - Overactive Bladder | Phase 3 | Terminated | Allergan | 41 | 2007-06-01 | 2014-01-24 |
| Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder Vesicare (solifenacin), Vesicare (solifenacin) plus behavioral modification - Overactive Bladder | Phase 3 | Terminated | Lahey Clinic | 12 | 2006-09-01 | 2018-04-04 |
| Refractory Urge Incontinence and Botox Injections Botulinum Toxin A, bladder detrusor muscle injection, Vehicle saline as placebo - Urinary Incontinence, Detrusor Overactivity | Phase 3 | Terminated | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 87 | 2006-06-01 | 2011-01-11 |
| Local Anesthetic Treatments for Overactive Bladder alkalinized xylocaine, placebo - Overactive Bladder | Phase 3 | Terminated | Frank Tu | 22 | 2006-03-01 | 2020-03-06 |
Urinary Incontinence (5) · Urinary Incontinence, Urge (3)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Lower Urinary Tract Symptoms (10) · Male Urogenital Diseases (10) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (10) · Urinary Bladder Diseases (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Urological Manifestations (10) · Urination Disorders (6) · Urinary Incontinence (1)
Botulinum Toxins, Type A (5) · Saline Solution (2) · abobotulinumtoxinA (2) · Dimethyl Sulfoxide (1) · Solifenacin Succinate (1) · mirabegron (1)
Ipsen (2) · Allergan (1) · Astellas Pharma Global Development, Inc. (1) · Center Eugene Marquis (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Frank Tu (1) · Lahey Clinic (1) · Mayo Clinic (1) · University of Zurich (1)
United States (6) · France (3) · Australia (2) · Belgium (2) · Canada (2) · Russia (2) · South Korea (2) · Turkey (Türkiye) (2) · Ukraine (2) · United Kingdom (2) · Argentina (1) · Brazil (1) · Chile (1) · Colombia (1) · Czechia (1)
Frank F. Tu, MD, MPH (1) · John T Stoffel, M.D. (1) · Linda Brubaker, MD (1) · Renaud de Crevoisier, MD (1) · Steven P Petrou, MD (1)
PMID 35400537, PMID 18499184, PMID 23218404
2015 (2), 2014 (1), 2016 (1)